Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of transcriptional and posttranscriptional mechanisms

Journal of Cell Biology

Volumn 148, Issue 3, 2000, Pages 543-556

  Servant, Marc J ^a   Coulombe, Philippe ^a   Turgeon, Benjamin ^a   Meloche, Sylvain ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CDK inhibitors; Cell cycle; Gene expression; Growth factors; Smooth muscle cells

Indexed keywords

ANGIOTENSIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLINE; GROWTH FACTOR; MESSENGER RNA; MITOGENIC AGENT; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN P27; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SMOOTH MUSCLE FIBER;

EID: 0034614943     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.148.3.543     Document Type: Article

References (111)

1. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery
2. Repression of p27(Kip1) synthesis by platelet-derived growth factor in BALB/c 3T3 cells
3. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27(Kip1)
4. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase
5. Angiotensin 11-stimulated protein synthesis in cultured vascular smooth muscle cells
6. Regulation of a calcium-dependent tyrosine kinase in vascular smooth muscle cells by angiotensin II and platelet-derived growth factor
7. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats
8. Agonist-selective regulation of polyphosphoinositide metabolism in pulmonary artery smooth muscle cells
9. Angiotensin II receptor and signal transduction mechanisms
10. Identification of human and mouse p19, a novel Cdk4 and Cdk6 inhibitor with homology to p16ink4
11. Downregulation of cyclin-dependent kinase 2 activity in vascular smooth muscle cells by p27(Kip1), an inhibitor of neointima formation in the rat carotid artery
12. Angiotensin II-1 receptors mediate both vasoconstrictor and hypertrophic responses in rat aortic smooth muscle cells
13. A reagent for the single-step simultaneous isolation of RNA. DNA and proteins from cell and tissue samples
14. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction
15. Platelet-derived growth factor receptor signals
16. Requirement or p27(Kip1) for restriction point control of the fibroblast cell cycle
17. Platelet-derived growth factor-induced destabilization of smooth muscle alpha-actin mRNA
18. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall
19. Smooth muscle DNA replication in response to angiotensin II is regulated differently in the neointima and media at different times after balloon injury in the rat carotid artery
20. 1 cyclins
21. Cultured or renal arteriolar smooth muscle cells: Mitogenic responses to angiotensin II
22. Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic smooth cells
23. WAF1, a potential mediator of p53 tumor suppression
24. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes
25. Angiotensin II induces hypertrophy, not hyperplasis, of cultured rat aortic smooth muscle cells
26. Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth cells
27. Cyclic AMP-mediated inhibition of angiotensin II-induced protein synthesis is associated with supression of tyrosine phosphorylation signaling in vascular smooth muscle cells
28. Vascular smooth muscle cell hypertrophy vs. hyperplasia
29. Mitogens for adult rat aortic vascular smooth muscle cells in serum-free primary culture
30. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CKIs)
31. Identification of newly transcribed RNA
32. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15
33. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
34. Growth suppression by p18, a p16 ink4/MTS1-and p14 ink4B/MTS2-related Cdk6 inhibitor, correlates with wild-type pRb function
35. p15(INK4B) is a potential effector of TGF-β induced cell cycle arrest
36. 1 cyclin-dependent kinases
37. A comparison of apparent mRNA half-life using kinetic labeling techniques vs decay following administration of transcriptional inhibitors
38. Angiotensin II-induced stimulation of smooth muscle alpha-actin expression by serum response factor and the homeodomain transcription factor MHox
39. Simultaneous induction of stimulatory and inhibitory signals by PDGF
40. Translational control of p27(Kip1) accumulation during the cell cycle
41. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6
42. Angiotensin II activates pp60c-src in vascular smooth muscle cells
43. A long-term receptor stimulation is requisite for angiotensin II-dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats
44. Optimization of the resolution of phosphoamino acids by one-dimensional thin-layer electrophoresis
45. Determination of phosphoamino acid composition by acid hydrolysis of protein blotted to Immobilon
46. 1 phase arrest mediated by an inhibitor (p27(Kip1)) of cyclin-dependent kinase-4 activation
47. Induction of p27(Kip1) degradation and anchorage independence by Ras through the MAP kinase signaling pathway
48. Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation
49. Role of transforming growth factor-β1 in the cellular growth response to angiotensin II
50. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors
51. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system
52. Characterization of the murine cyclin-dependent kinase inhibitor gene p27(Kip1)
53. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts
54. Cyclin D1 expression is regulated positively by the p42/p44mapk and negatively by the p38/HOGmapk pathway
55. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells
56. Cloning of p57(KIP2). A cyclin-dependent kinase inhibitor with unique domain structure and a tissue distribution
57. 3 leads to the induced differentiation of the myelomonocytic cell line U937
58. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor
59. The transforming growth factor-beta family
60. p57(KIP2), a structurally distinct member of the p21(CIPI) Cdk inhibitor family, is a candidate tumor suppressor gene
61. D-type cyclin-dependent kinase activity in mammalian cells
62. 1/S transition
63. Enhance ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest
64. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells
65. Principles of CDK regulation
66. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides
67. Mechanisms of cyclin-dependent kinase inactivation by progestins
68. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
69. Interleukin-2-mediated elimination of p27(Kip1) cyclin-dependent kinase inhibitor prevented by rapamycin
70. 1-to-S phase transition
71. Control of hypertrophic versus hyperplastic growth vascular smooth muscle cells
72. Regulation of differentiation of vascular smooth muscle cells
73. Transforming growth factor-β-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells
74. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
75. 1 events and regulation of cell proliferation
76. Efficacy of agonist-stimulated MEK activation determines the susceptibility of mitogen-activated protein (MAP) kinase to inhibition in rat aortic smooth muscle cells
77. Focal adhesion kinase is abundant in developing blood vessels and elevation of its phosphotyrosine content in vascular smooth muscle cells is a rapid response to angiotensin II
78. Cloning of p27(Kip1), a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
79. p27(Kip1), a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest
80. Peptide growth factors and their receptors
81. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β
82. 0 state) in fibroblasts
83. Platelet-derived growth factor and angiotensin II cause increases in cytosolic free calcium by different mechanisms in vascular smooth muscle cells
84. The pathogenesis of atherosclerosis: A perspective for the 1990s
85. Immediate-early gene expression in response to hypertrophic and proliferative stimuli in pulmonary arterial smooth muscle cells
86. Crystal structure of the p27(Kip1) cyclin-dependent kinase inhibitor bound to the cyclin A-Cdk2 complex
87. Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells
88. Replication of smooth muscle cells in vascular disease
89. Cyclin dependent kinase activating kinases
90. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
91. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells
92. Cyclin E-Cdk2 is a regulator of p27(Kip1)
93. 1 phase progression: Cycling on cue
94. 1 cyclin-dependent kinases
95. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells
96. Masked and translatable messenger ribonucleoproteins in higher eukaryotes
97. Mitogenic effect of angiotensin II on rat carotid arteries and type II and III mesenteric microvessels but not type I mesenteric microvessels is mediated by endogenous basic fibroblast growth factor
98. 1 phase required for p27(Kip1) downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts
99. Angiotensin II receptors and angiotensin II receptor antagonists
100. 1 cyclin-Cdk protein kinase activity, is related to p21
101. Angiotensin II stimulates two myelin basic protein/microtubule-associated protein 2 kinases in cultured vascular smooth muscle cells
102. Distinct roles for cyclin-dependent kinases in cell cycle control
103. α1-Adrenoreceptor blockade reduces the angiotensin II-induced vascular smooth muscle cell DNA synthesis in the rat thoracic aorta and carotid artery
104. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27(Kip1)
105. 1 progression through the independent regulation of cyclin D1 and p27(Kip1)
106. Temporally and spacially coordinated expression of cell cycle regulatory factors after angioplasty
107. The retinoblastoma protein and cell cycle control
108. 1 cyclins and the CDK inhibitor p27(Kip1) by platelet-derived growth factor and plasma factors in density arrested fibroblasts
109. p21 is a universal inhibitor of cyclin kinases
110. Molecular characterization of the cyclin-dependent kinase inhibitor p27 promoter